Key result
Corosolic acid attenuated hepatic lipid accumulation, liver steatosis, and inflammation in HepG2 cells and hyperlipidemic mice via AMPK/SREBPs and NF-κB/MAPK signaling pathways.
Why the study?
Corosolic acid has known antidiabetic, antioxidant, and anticancer effects, but its effects on hepatic lipid accumulation needed examination.
Does Corosolic acid attenuate hepatic lipid accumulation and inflammation in HepG2 cells and tyloxapol-induced hyperlipidemia mice?
Population
HepG2 cells and tyloxapol-induced hyperlipidemia ICR mice
Comparison
Corosolic acid treatment
Design
Preclinical laboratory and animal study
Authors
Loading...
Corosolic acid merits further preclinical testing for steatosis; leaves open translation to human hyperlipidemia.
Does Corosolic acid attenuate hepatic lipid accumulation and inflammation in HepG2 cells and tyloxapol-induced hyperlipidemia mice?
Corosolic acid demonstrates potential as an antihyperlipidemic and anti-hepatic steatosis agent through modulation of AMPK/SREBPs and NF-κB/MAPK pathways in preclinical models.
Zhang et al. (2020) studied Hepatic lipid accumulation and hyperlipidemia. Corosolic acid vs. Tyloxapol-induced hyperlipidemia without corosolic acid was evaluated on Hepatic lipid accumulation and inflammatory response. Corosolic acid attenuated hepatic lipid accumulation, liver steatosis, and inflammation in HepG2 cells and hyperlipidemic mice via AMPK/SREBPs and NF-κB/MAPK signaling pathways.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: